Forums for Expressing Concerns

This publication has 25 references indexed in Scilit:

• Sources of variability on the estimate of treatment effect in the PROWESS trial: Implications for the design and conduct of future studies in severe sepsis*
  Critical Care Medicine, 2004
• Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia
  Blood, 2003
• The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*
  Critical Care Medicine, 2003
• Drotrecogin Alfa (Activated) Treatment of Older Patients with Severe Sepsis
  Clinical Infectious Diseases, 2003
• Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial
  Intensive Care Medicine, 2003
• Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*
  Critical Care Medicine, 2003
• Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis*
  Critical Care Medicine, 2003
• Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis
  Critical Care Medicine, 2003
• Pharmacokinetic‐pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis
  Clinical Pharmacology & Therapeutics, 2002
• Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
  New England Journal of Medicine, 2001